Press Releases

AUSTIN, Texas , Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its third quarter 2021 financial results after market close on Wednesday, November 3, 2021 .

AUSTIN, Texas , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23 rd Annual Global Investment Conference and the Cantor

• Lumos Pharma strengthens leadership team with promotion of John McKew , PhD to President, and addition of David B. Karpf , MD as Chief Medical Officer and Mark Bach , MD, PhD to Advisory Board • Screening and enrollment of OraGrowtH210 and OraGrowtH212 Trials progress AUSTIN, Texas , Aug.

AUSTIN, Texas , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that experienced endocrinologist and pharma executive, David B. Karpf , MD, joined the Company August 3, 2021 as

AUSTIN, Texas , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that current Chief Operating Officer and Chief Scientific Officer, John McKew , PhD, was promoted to President of

AUSTIN, Texas , July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach , M.D., Ph.D., accepted his appointment to the Company’s Clinical Scientific Advisory Board (CSAB)

AUSTIN, Texas , July 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its second quarter 2021 financial results before market open on Thursday, August 5, 2021 .

OraGrowtH210 Trial in PGHD primary outcome 6-month data now anticipated in 2H2023; treatment period to be extended to 12 months OraGrowtH212 PK/PD Trial initiated in Q2 2021; treatment period to be extended to 12 months with primary data at 6-months Cash balance as of June 30, 2021 of $107.7

Single-Center Phase 2 Trial to Study the Pharmacokinetics/Pharmacodynamics (PK/PD) and  Unique Pulsatile Mechanism of Action of LUM-201 at Two Dose Levels AUSTIN, Texas , June 28, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on

AUSTIN, Texas , May 19, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3,